Henan Lingrui Pharmaceutical Co., Ltd.

SHSE:600285 Voorraadrapport

Marktkapitalisatie: CN¥12.1b

Henan Lingrui Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Wei Xiong

Algemeen directeur

CN¥1.8m

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO1.5yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Oct 28
An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

Oct 13
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

Aug 07
If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Jul 03
A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 07
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

May 02
Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 04
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Feb 29
Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

CEO

Wei Xiong (39 yo)

1.5yrs

Tenure

CN¥1,804,900

Compensatie

Mr. Wei Xiong serves as General Manager and Chairman at Henan Lingrui Pharmaceutical Co. Ltd. since May 18, 2023 and served as its Managing Director.